
Esperion Therapeutics (ESPR) Stock Forecast & Price Target
Esperion Therapeutics (ESPR) Analyst Ratings
Bulls say
Esperion Therapeutics Inc is experiencing significant financial growth, as evidenced by a 53% increase in product revenue to $31.1 million for the latest quarter, driven by both retail prescription growth of 12% from the previous quarter and a remarkable 44% increase from the same quarter last year. In addition, the company benefits from strong marketing support from partner Daiichi Sankyo Europe, contributing to a 19% sequential rise in royalty revenues, indicating a robust demand for their products NILEMDO and NUSTENDI. Furthermore, the expansion of preferred commercial and Medicare coverage to over 92% and 65%, respectively, reinforces the expected positive sales trajectory and positions the company well for sustained long-term growth in the pharmaceutical market.
Bears say
Esperion Therapeutics Inc. has faced challenges in establishing a consistent path to profitability, reflected in its history of operating losses and incremental reductions in sales estimates for the current year. The company is at risk from potential competition, as breakthrough therapies may render its existing products obsolete, posing a significant threat to its future viability. Additionally, the recent changes in healthcare management of LDL-C levels, influenced by CLEAR Outcomes data, may further complicate Esperion's market position and financial outlook.
This aggregate rating is based on analysts' research of Esperion Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Esperion Therapeutics (ESPR) Analyst Forecast & Price Prediction
Start investing in Esperion Therapeutics (ESPR)
Order type
Buy in
Order amount
Est. shares
0 shares